Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02345031 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of AUT00063 Versus Placebo in Age-Related Hearing Loss
A Phase 2 study of Age-Related Hearing Loss, sponsored by Autifony Therapeutics Limited.
- Completed
- Registry status
- Phase 2
- Development phase
- 78
- Enrollment target
- 13
- Study locations
NCT02345031 is a Phase 2 study of Age-Related Hearing Loss that has completed, run by Autifony Therapeutics Limited. The registered enrollment target is 78 participants. The trial reports 13 study locations across 10 states.
The verdict
NCT02345031, a Phase 2 study of Age-Related Hearing Loss, has completed, sponsored by Autifony Therapeutics Limited.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 78 participants
- Enrollment target
- 13
- Study locations
Study Summary
This study aims to demonstrate that the investigational drug AUT00063 is effective and safe in the treatment of age-related hearing loss.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG AUT00063
Study Locations (13)
Florida
- ENT Associates of South Florida - Boca Raton
- QPS MRA (Miami Research Associates) - Miami
- University of South Florida - Tampa
North Carolina
- PMG Research Inc. - Wilmington
- Piedmont Ear, Nose, & Throat Associates - Winston-Salem
California
- Sacramento ENT - Sacramento
Colorado
- Colorado ENT and Allergy - Colorado Springs
Kentucky
- University of Louisville - Louisville
Minnesota
- Mayo Clinic - Rochester
Mississippi
- The University of Mississippi Medical Center - Jackson
New York
- Long Island Jewish Medical Center - New Hyde Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2015-01 |
| Est. Completion | 2016-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02345031
The ClinicalTrials.gov registry entry for NCT02345031 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Autifony Therapeutics Limited, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Age-Related Hearing Loss appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02345031 reports 13 study locations spanning 10 distinct geographic areas - top geographies include Florida, North Carolina, California.
Frequently Asked Questions
What is clinical trial NCT02345031 about?
NCT02345031 is a clinical study titled "Efficacy and Safety of AUT00063 Versus Placebo in Age-Related Hearing Loss". This study aims to demonstrate that the investigational drug AUT00063 is effective and safe in the treatment of age-related hearing loss.
What is the current status of trial NCT02345031?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 78 participants. The study started on 2015-01. Estimated completion is 2016-06.
What conditions does trial NCT02345031 study?
This clinical trial studies the following conditions: Age-Related Hearing Loss.
What interventions are being tested in trial NCT02345031?
The interventions under investigation include: Placebo (DRUG), AUT00063 (DRUG).
Who is sponsoring clinical trial NCT02345031?
This trial is sponsored by Autifony Therapeutics Limited, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02345031 being conducted?
This trial has 13 study locations across California, Colorado, Florida, Kentucky, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.